PASG

Passage Bio, Inc.

A clinical-stage gene therapy company developing one-time treatments for rare brain and nervous-system diseases. Founded in 2019 as a spinout of the University of Pennsylvania's Gene Therapy Program, it builds on the work of gene-therapy pioneer James Wilson. Its name comes from "passaging" — the lab process of growing and purifying the harmless viruses that carry therapeutic genes into cells. Its lead programs target rare disorders such as GM1 gangliosidosis and Krabbe disease.